Sym004 exhibited significant tumor growth inhibition in a subset of ESCC cell lines in vitro and in vivo with pronounced activities in comparison with other anti-EGFR monoclonal antibodies, cetuximab and panitumumab. This evidence concerns the gene EGFR and neoplasm.